NCATS - Accepting Proposals to Collaborate with the Therapeutics for Rare and Neglected Diseases (TRND) and Bridging Interventional Development Gaps (BrIDGs) programs

The NCATS Therapeutic Development Branch (TDB) is accepting proposals to collaborate with the Therapeutics for Rare and Neglected Diseases (TRND) and Bridging Interventional Development Gaps (BrIDGs) programs. Proposals are due Sept. 30, 2023.

The goal of the TDB within the NCATS intramural Division of Preclinical Innovation is to encourage and speed the development of new treatments and technologies for diseases with high unmet medical needs, especially rare conditions and neglected tropical infectious diseases. TDB seeks to collaborate with academic, nonprofit, industry and other government researchers from within and outside the United States. By collaborating with TDB, partners with promising new therapeutic candidates benefit from the significant preclinical development expertise and dedicated project management of our intramural scientists.

TDB provides in-kind support — not direct funding to collaborators — to advance the development of promising therapeutic candidates and novel platform technologies, from lead optimization to submission of an Investigational New Drug application.

Click here to learn more!